Zero Order vs. First Order Release: The Six Shapes Behind Extended-Release Drugs

A release curve is not a blood-level curve

A release curve measures the amount of drug leaving a tablet, capsule, bead, or matrix. A plasma curve measures what is left after gastric emptying, dissolution, absorption, distribution, metabolism, and elimination.

The two are related, but they are not the same. Even a perfectly constant dissolution curve can produce a plasma curve that rises, plateaus, and falls, as the body has enzymes that begin to clear the drug the moment the drug arrives.

The plotting trap. On a cumulative-release chart, zero order is a straight rising line. On a release-rate chart, zero order is a flat horizontal line. Same data. Opposite pictures. Check the y-axis before you call a curve flat.

The curve map

Each shape below is paired with marketed products whose labels describe the delivery mechanism. Labels establish mechanism. Fitting a kinetic model is a separate exercise.

Zero order: the same amount every hour

The capsule or tablet lets go of the same number of milligrams every hour. The rate holds steady. Total released climbs in a straight line until there is nothing left inside. The ideal mathematical model is: M(t) = k₀t.

Osmotic systems come closest. Procardia XL uses a semipermeable membrane, an osmotic push layer, and a laser-drilled orifice, and its label describes nifedipine delivery as approximately constant over 24 hours while the osmotic gradient holds. Ditropan XL applies the same idea to oxybutynin.

Note the word approximately. Zero order is what the engineer aims at. Real tablets take a moment to get going, slow down as they empty, and move through guts that differ from one person to the next.

First order: a fixed fraction of what remains

First order is front-loaded. More drug inside means more drug leaving. As the remaining amount falls, so does the rate. Equal time intervals remove the same fraction rather than the same milligrams. The ideal mathematical model is: F(t) = 1 − e⁻ᵏᵗ.

All three lines deliver the entire dose. Only the timing differs.

A drug crossing a membrane can look first-order-like, because the less drug there is inside, the less pressure there is pushing it out. Effexor XR is the mechanism example: venlafaxine diffuses through coatings on drug-containing spheroids, and the label reports lower, later peaks than immediate-release venlafaxine. The label stops there. It does not declare a kinetic fit.

First order is not failed zero order. A falling input rate may be exactly what the formulation was built to produce, and it may deliver the intended exposure. The right curve is whichever one matches the drug, the dose, and the clinical job.

Matrix release: diffusion gets harder with distance

Many matrix tablets sit between the simple labels. Fluid soaks in. Drug dissolves and works its way out. The emptied outer layer thickens, so each molecule has farther to travel than the one before it, and the rate slows. Under Higuchi's classic assumptions, cumulative release is proportional to the square root of time. The ideal mathematical model is: M(t) = kH√t.

There is a second pattern, where the matrix itself disappears instead of drug travelling out through it. Hixson–Crowell kinetics track the shrinking surface area of an eroding solid. Erodible and lipid-based systems tend this way.

Glucophage XR uses a dual hydrophilic-polymer matrix that hydrates and swells. Klor-Con holds potassium chloride in a wax matrix. Those labels establish mechanisms. They do not prove that any particular dissolution dataset is Higuchi rather than first order, zero order, Hixson–Crowell, or a mix.

Why real matrices resist one-word labels. Swelling, pore formation, diffusion, erosion, lipid digestion, drug solubility, and geometry can all shift during a single run. One formulation can change mechanisms partway through.

The shapes that are not chasing flat

Delayed release does nothing through a lag phase, then opens after a trigger such as a pH change. A sublingual tablet does the opposite, skipping the gut entirely. Omeprazole delayed-release capsules use enteric-coated granules because omeprazole is unstable in acid. The design protects the drug and picks a location. Peak height is beside the point.

Pulsatile release schedules distinct inputs. Adderall XR carries two bead populations for double-pulsed amphetamine delivery.

Ascending release gets faster as it goes. Concerta starts with an immediate-release overcoat, then an osmotic trilayer system increases methylphenidate release over roughly six to seven hours using a built-in concentration gradient. It is an osmotic system built to speed up rather than hold steady.

Delayed is not extended. Both sit under the modified-release umbrella. Delayed release moves the start. Extended release lengthens the window. Some products do both.

The memorable version: zero order holds the rate, first order loses speed, delayed release waits, pulsatile release schedules, ascending release ramps.

What problem is each curve solving?

Release engineering starts with the job, not the mechanism. Four jobs recur.

Peak control. Bring down a fast dump of drug that concentrates side effects, or that irritates the tissue it sits against.

Coverage. Keep drug arriving after an immediate-release dose would have run out.

Timing and location. Protect an acid-labile drug, bypass the stomach, or match release to a daily need.

Adherence. Replace several daily doses with one, where the pharmacology allows it.

One product often serves several jobs. Procardia XL smooths nifedipine levels and supports once-daily dosing. Concerta stretches coverage with a rising input.

Where MINX fits, and where the evidence stops

MINX is an oral minoxidil capsule built around a lipid matrix, compounded per prescription under section 503A. The drug is dispersed in a lipid phase designed to slow release and approach a near-constant rate across the intended window. The goal is a lower peak.

In the fed participant of our two-person pilot, measured minoxidil concentrations were still rising at hour eight. A fitted model, not a measured blood draw, put the peak around 6.5 ng/mL at roughly hours nine to ten.

That shows the drug was still arriving eight hours later, in one person who had eaten. It is not proof of zero-order release, and we will not call it that until the dissolution data earn the label. It says nothing about clinical benefit, about split dosing, or about hair growth. The fasted participant showed much lower exposure, so food dependence is part of the story too.

How you would actually test for zero order

A smooth-looking line is not enough. The real test is a model comparison built on replicate dissolution runs.

Plot both views. Cumulative mass released and release rate over time, showing replicate variability instead of a single mean line.

Fit competing models. Compare zero order, first order, Higuchi, Hixson–Crowell, and Korsmeyer–Peppas across a prespecified window. Korsmeyer–Peppas is the power law whose exponent hints at mechanism. Its thresholds shift with dosage-form geometry, so a number from a sphere does not mean what the same number means from a slab.

Inspect residuals. A high R² hides systematic curvature. Residual plots, confidence intervals, and an information criterion such as AIC show more.

Challenge the mechanism. Repeat across justified media, agitation conditions, and food-relevant conditions. See whether the conclusion survives reasonable changes to the test.

Keep the claims separated. Dissolution supports release kinetics. Pharmacokinetics supports blood-level claims. Clinical trials support efficacy and safety claims.

That is the three-layer rule: release curve, then plasma curve, then clinical outcome. Evidence for one layer does not carry to the next.

The gap between the beaker and the bloodstream is where most of the honest uncertainty in this field lives. It is also where a good number of the open questions about minoxidil sit.

MINX is a 503A compounded formulation, available by prescription, and is not an FDA-approved drug. Talk to a physician before starting or changing any treatment, especially if you have any history of cardiovascular disease.

Frequently asked questions

Is every extended-release drug zero order?

No. Extended release describes a modified time course, not one curve. The shape may be constant, declining, delayed, pulsatile, ascending, or mixed. Which one applies comes from the data, not from the label on the box.

Does zero-order release mean a flat blood level?

No. The gut absorbs at its own pace and the body clears at its own pace, and between them they reshape whatever the capsule delivers. A near-constant release rate still gives a blood level that rises, plateaus, and falls.

Is first-order release worse than zero order?

It is a different shape. If a drug needs to stay above an effective level and its peak is harmless, first order is adequate and cheaper to manufacture. If the dose-limiting problem sits at the top of the curve, a flatter profile helps.

Can a compounded product be called zero order?

Only if its own measured release data support that fit across a defined window. A compounder needs data for its specific preparation. Borrowing a conclusion from someone else's formulation does not count.

What release pattern does MINX follow?

The lipid matrix is designed to slow release and approach a near-constant rate. Erodible systems of this kind tend toward erosion-controlled behavior rather than pure diffusion. We have not published a model-comparison fit, so we describe the design target and stop there.

What peak does MINX produce?

In a two-person pilot, levels were still rising when sampling ended at hour eight. Our model puts the peak around 6.5 ng/mL at roughly hours nine to ten, against about 37 ng/mL half an hour after an immediate-release tablet. That figure is modeled, from two people, and sampling stopped before the curve turned over.

Does a blood level tell you how well minoxidil is working?

Not directly. Minoxidil is converted into minoxidil sulfate in the liver and the follicle by an enzyme whose activity varies from person to person, and everyday drugs and supplements compete for that same enzyme. Minoxidil sulfate is unstable enough that it has not been quantified in human serum. A blood level is an input to that conversion. It is not a measurement of the effect, and that is true of every oral minoxidil product.